Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
09:31pm, Tuesday, 04'th Nov 2025
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street est
Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates
06:21pm, Tuesday, 04'th Nov 2025
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $1.06 per share a year ago.
Supernus Announces Third Quarter 2025 Financial Results
04:01pm, Tuesday, 04'th Nov 2025
ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals, Inc. $SUPN Shares Bought by Cwm LLC
04:05am, Sunday, 02'nd Nov 2025
Cwm LLC boosted its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 92.4% during the second quarter, according to the company in its most recent filing with the Securities and E
Here's Why Supernus Pharmaceuticals (SUPN) is a Great Momentum Stock to Buy
01:01pm, Wednesday, 29'th Oct 2025
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
11:07am, Tuesday, 28'th Oct 2025
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
10:16am, Monday, 27'th Oct 2025
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Supernus (SUPN) is Poised to Beat Earnings Estimates Again
01:11pm, Wednesday, 22'nd Oct 2025
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
05:00pm, Tuesday, 21'st Oct 2025
ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Can 4 Relative Price Strength Stocks Defy Market Swings?
04:11pm, Wednesday, 15'th Oct 2025
UNFI, TDOC, SUPN and BRP shine with strong relative price strength, earnings momentum, and analyst upgrades amid volatile markets.
Supernus Pharmaceuticals (SUPN) Is Up 2.81% in One Week: What You Should Know
01:01pm, Monday, 13'th Oct 2025
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run?
10:16am, Friday, 10'th Oct 2025
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are You Looking for a Top Momentum Pick? Why Supernus Pharmaceuticals (SUPN) is a Great Choice
01:01pm, Thursday, 25'th Sep 2025
Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue?
10:15am, Tuesday, 23'rd Sep 2025
Supernus (SUPN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Supernus Pharmaceuticals: Heading In The Right Direction
04:05pm, Wednesday, 17'th Sep 2025
Supernus Pharmaceuticals shares have rallied nicely after strong 2Q25 results, driven by robust Qelbree and Gocovri sales and a surge in Zurzuvae revenue. Supernus' recent acquisition of Sage Therapeu
